ghk-cu low immunogenicity or antibody formation risk An evidence-based strategy for assessing the of Implementing a Clinical Immunogenicity Strategy – The tri-peptide GHK-Cu complex ameliorates – GHK-CU Making Skin Worse: Complete

Note: Nearly all data is from animal or in vitro models

bFGF production increases 230% with LED irradiation (625-635 nm), creating synergistic effects for cell proliferation and migration

Ease of consumption If swallowing big pills is a problem, the choice between the liquid and tablet B12 formulation is clear

And this was confirmed on MRI

No human neuroregeneration data at all It bears repeating because it is so often elided: there are no completed, published, controlled human trials showing that either BPC-157 or TB-500/thymosin beta-4 regenerates nerves or treats a neurological disease

July 23 BPC-157 Proposed use : ulcerative colitis (an inflammatory bowel disease) Outcome : Yes Margin : 8-6 in favor, with one abstention What the FDA was saying : There is a lack of evidence to support using